Highlighted passage: Included in this study were patients with biopsy-confirmed mNSCLC who had not yet progressed or experienced serious adverse events to single-agent chemotherapy, and thus had reasonable options for further palliative systemic therapy. Patients must have been discharged to a SNF with an intention for further therapy once functional status permitted.
Fig 1. Sankey diagram depicting planned systemic therapy, proportion of patients who received said therapy, and treatment response. Chemo, any chemotherapy containing regimen; ICI, immune checkpoint inhibitor; TKI, tyrosine kinase inhibitor. Of the total 427 patients, 173 (40.5%) had a hospital readmission within the subsequent 30 days after discharge to a SNF. Only 229 (53.6%) ever managed to return to an outpatient oncology visit, and only 131 (30.7%) received any subsequent systemic therapy. This proportion varied by the intended therapy (Fig 1; Table 2), with 40 of the 54 planned for a TKI (74.1%), 42 of the 130 planned for ICI (32.3%), and 49 of the 243 planned for cytotoxic chemotherapy (20.2%) receiving further therapy (P < .001).
Wow. Data from @n8pennell.bsky.social & team #JCOOP confirming the care fragmentation many of us see in real life.
Patients with metastatic NSCLC whose docs felt it was reasonable for them to restart treatment after rehabbing at a SNF:
- Only 54% saw outpt onc again
- 31% restarted tx
